173 related articles for article (PubMed ID: 24079654)
1. Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis.
Thet Z; Win AK; Pedagogos E; Beavis J; Crikis S; Nelson C
BMC Nephrol; 2013 Oct; 14():205. PubMed ID: 24079654
[TBL] [Abstract][Full Text] [Related]
2. Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis—sevelamer hydrochloride, calcium carbonate, and bixalomer.
Sanai T; Tada H; Ono T; Fukumitsu T
Hemodial Int; 2015 Jan; 19(1):54-9. PubMed ID: 24980286
[TBL] [Abstract][Full Text] [Related]
3. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
Keith MS; Wilson RJ; Preston P; Copley JB
Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
Zhou T; Li H; Xie W; Lin Z
Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
Suñer M; Guerrero A; Montes R; Rivera M; Ruiz A; Martínez-García M; Pérez-Valdivia MA; Mateos J
Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
[TBL] [Abstract][Full Text] [Related]
6. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.
Ramos R; Moreso F; Borras M; Ponz E; Buades JM; Teixidó J; Morey A; Garcia C; Vera M; Doñate MT; de Arellano MR; Barbosa F; González MT
Perit Dial Int; 2007; 27(6):697-701. PubMed ID: 17984434
[TBL] [Abstract][Full Text] [Related]
7. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
Noto L
J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
[TBL] [Abstract][Full Text] [Related]
8. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
[TBL] [Abstract][Full Text] [Related]
9. Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients.
Filiopoulos V; Koutis I; Trompouki S; Hadjiyannakos D; Lazarou D; Vlassopoulos D
Ther Apher Dial; 2011 Feb; 15(1):20-7. PubMed ID: 21272248
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
11. The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
Wilson RJ; Keith MS; Preston P; Copley JB
Adv Ther; 2013 Dec; 30(12):1100-10. PubMed ID: 24307220
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
13. Sevelamer worsens metabolic acidosis in hemodialysis patients.
De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
[TBL] [Abstract][Full Text] [Related]
14. Metabolic acidosis in peritoneal dialysis patients: the role of residual renal function.
Tian XK; Shan YS; Zhe XW; Cheng LT; Wang T
Blood Purif; 2005; 23(6):459-65. PubMed ID: 16244471
[TBL] [Abstract][Full Text] [Related]
15. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Pai AB; Shepler BM
Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
[TBL] [Abstract][Full Text] [Related]
16. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.
Brewster UC; Ciampi MA; Abu-Alfa AK; Reilly RF
Nephrology (Carlton); 2006 Apr; 11(2):142-6. PubMed ID: 16669977
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD.
Bushinsky DA; Hostetter T; Klaerner G; Stasiv Y; Lockey C; McNulty S; Lee A; Parsell D; Mathur V; Li E; Buysse J; Alpern R
Clin J Am Soc Nephrol; 2018 Jan; 13(1):26-35. PubMed ID: 29102959
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of low HCO3- levels in peritoneal dialysis patients.
Kasimatis E; Maksich D; Jassal V; Bargman JM; Oreopoulos DG
Clin Nephrol; 2005 Apr; 63(4):290-6. PubMed ID: 15847256
[TBL] [Abstract][Full Text] [Related]
19. The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
Beaubien-Souligny W; Bezzaoucha S; Pichette V; Lafrance JP; Bell R; Lamarche C; Ouimet D; Vallee M
Int Urol Nephrol; 2015 Jul; 47(7):1165-71. PubMed ID: 25982583
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.
Tonelli M; Wiebe N; Culleton B; Lee H; Klarenbach S; Shrive F; Manns B;
Nephrol Dial Transplant; 2007 Oct; 22(10):2856-66. PubMed ID: 17906326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]